Novartis Financial Statements From 2010 to 2020

<div class='circular--portrait' style='background:#347AFC;color: #ffffff;font-size:4em;padding-top: 25px;;'>NO</div>
NVS -- USA Stock  

Report: 21st of July 2020  

Novartis financial statements provide useful quartarly and yearly information to potential investors in Novartis AG about the current and past financial position of the company, as well as its overall management performance and changes in basic fundamentals over time. There are over ninety available fundamental ratios for Novartis which can be analyzed over time and compared to other ratios. Please make sure you to check Novartis last-minute fundamental performance against the performance between 2010 and 2020 to make sure the trends are evolving in the right direction. Novartis Tangible Asset Value is relatively stable at the moment as compared to the past year. Novartis reported last year Tangible Asset Value of 63.06 Billion. As of 07/10/2020, Working Capital is likely to grow to about 1.3 B, while Market Capitalization is likely to drop slightly above 218.1 B.

Search Fundamental Trends

 
Refresh
Check Novartis financial statements over time to gain insight into the future company performance. Apply historical fundamental analysis to find patterns among financial statement drivers such as Consolidated Income of 12.1 B, Cost of Revenue of 14.2 B or Earning Before Interest and Taxes EBIT of 14.8 B, as well as many exotic indicators such as Asset Turnover of 0.37, Book Value per Share of 29.65 or Current Ratio of 1.05. This can be a perfect complement to check Novartis Valuation or Volatility. It can also complement various Novartis Technical models. Additionally, see the analysis of Novartis Correlation with competitors.

  Novartis Revenues

Novartis Balance Sheet

Current ValueLast YearHistorical Average 10 Year Trend
Total Assets134.4 B118.4 B125.6 B
Increasing
Slightly volatile
Cash and Equivalents10.2 B11.1 B7.9 B
Increasing
Slightly volatile
Investments12.7 B11.5 B15.9 B
Decreasing
Slightly volatile
Investments Current342.8 M334 M2.5 B
Decreasing
Slightly volatile
Investments Non Current11.4 B11.2 B13.3 B
Decreasing
Very volatile
Property Plant and Equipment Net13.9 B13.7 B15.7 B
Decreasing
Slightly volatile
Inventory6.8 BB6.5 B
Increasing
Stable
Tax Assets8.7 B8.2 B7.9 B
Increasing
Slightly volatile
Trade and Non Trade Receivables8.1 B8.3 B8.8 B
Decreasing
Slightly volatile
Trade and Non Trade Payables5.9 B5.4 B5.3 B
Increasing
Slightly volatile
Goodwill and Intangible Assets62.9 B55.3 B58.1 B
Increasing
Slightly volatile
Total Liabilities64.8 B62.8 B55.8 B
Increasing
Slightly volatile
Shareholders Equity69.2 B55.5 B69.7 B
Increasing
Stable
Current Assets32.5 B29.5 B29.8 B
Increasing
Stable
Assets Non Current102 B88.9 B95.9 B
Increasing
Slightly volatile
Current Liabilities29.2 B28.3 B25.1 B
Increasing
Slightly volatile
Liabilities Non Current35.6 B34.6 B30.7 B
Increasing
Slightly volatile
Tax Liabilities9.1 B8.1 B8.3 B
Increasing
Stable
Total Debt28.7 B29.3 B23.3 B
Increasing
Slightly volatile
Debt Current7.7 B7.3 B6.6 B
Increasing
Slightly volatile
Debt Non Current21 B22.1 B16.8 B
Increasing
Slightly volatile
Shareholders Equity USD69.2 B55.5 B69.7 B
Increasing
Stable
Cash and Equivalents USD10.2 B11.1 B7.9 B
Increasing
Slightly volatile
Total Debt USD28.7 B29.3 B23.3 B
Increasing
Slightly volatile

Novartis Income Statement

Current ValueLast YearHistorical Average 10 Year Trend
Revenues46.8 B48.7 B49.8 B
Decreasing
Slightly volatile
Cost of Revenue14.2 B14.4 B15.7 B
Decreasing
Stable
Selling General and Administrative Expense13.8 B14.4 B14.6 B
Decreasing
Slightly volatile
Research and Development Expense10.1 B9.4 B8.9 B
Increasing
Slightly volatile
Operating Expenses25.3 B27.2 B25.9 B
Decreasing
Stable
Interest Expense868.4 M850 M743.2 M
Increasing
Slightly volatile
Income Tax Expense1.6 B1.8 B1.5 B
Increasing
Very volatile
Net Loss Income from Discontinued Operations(4.7 B)(4.6 B)(1.8 B)
Decreasing
Slightly volatile
Consolidated Income12.1 B11.7 B10.5 B
Increasing
Stable
Net Income to Non Controlling Interests5.1 MM45.9 M
Decreasing
Slightly volatile
Net Income12.1 B11.7 B10.4 B
Increasing
Stable
Net Income Common Stock12.1 B11.7 B10.4 B
Increasing
Stable
Weighted Average Shares2.6 B2.3 B2.4 B
Increasing
Slightly volatile
Earning Before Interest and Taxes EBIT14.8 B14.4 B12.7 B
Increasing
Slightly volatile
Revenues USD46.8 B48.7 B49.8 B
Decreasing
Slightly volatile
Net Income Common Stock USD12.1 B11.7 B10.4 B
Increasing
Stable
Earning Before Interest and Taxes USD14.8 B14.4 B12.7 B
Increasing
Slightly volatile
Gross Profit32.6 B34.3 B34.1 B
Decreasing
Slightly volatile
Operating Income7.3 B7.1 B8.2 B
Decreasing
Slightly volatile

Novartis Cash Flow Statement

Current ValueLast YearHistorical Average 10 Year Trend
Capital Expenditure(563.2 M)(522 M)(1.7 B)
Increasing
Slightly volatile
Net Cash Flow Business Acquisitions and Disposals(4.1 B)(3.8 B)(2.6 B)
Decreasing
Stable
Net Cash Flow Investment Acquisitions and Disposals3.4 B3.2 B(340 M)
Increasing
Slightly volatile
Net Cash Flow from Financing(14 B)(13.6 B)(8.2 B)
Decreasing
Slightly volatile
Issuance Repayment of Debt Securities (5.1 B)(5 B)682.8 M
Decreasing
Stable
Issuance Purchase of Equity Shares(5.5 B)(5.3 B)(2.9 B)
Decreasing
Slightly volatile
Payment of Dividends and Other Cash Distributions (7.2 B)(6.6 B)(6.2 B)
Decreasing
Slightly volatile
Net Cash Flow from Investing(2.4 B)(2.2 B)(4.6 B)
Increasing
Stable
Net Cash Flow from Operations12.7 B13.6 B13.1 B
Decreasing
Very volatile
Effect of Exchange Rate Changes on Cash (264.2 M)(257.4 M)(173.4 M)
Decreasing
Slightly volatile
Net Cash Flow or Change in Cash and Cash Equivalents(2.2 B)(2.2 B)403 M
Decreasing
Very volatile

Financial Ratios

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share5.25.124.41
Increasing
Slightly volatile
Earnings per Diluted Share5.155.064.367
Increasing
Slightly volatile
Earnings per Basic Share USD5.25.124.41
Increasing
Slightly volatile
Dividends per Basic Common Share14.5113.4524.4935
Increasing
Slightly volatile
Return on Average Equity0.180.1750.1504
Increasing
Stable
Return on Average Assets0.08210.0890.0829
Decreasing
Very volatile
Return on Invested Capital0.260.2530.2255
Increasing
Stable
Gross Margin0.660.7040.6822
Decreasing
Slightly volatile
Profit Margin0.240.2410.2093
Increasing
Slightly volatile
EBITDA Margin0.30.2950.2549
Increasing
Slightly volatile
Return on Sales0.30.2950.2549
Increasing
Slightly volatile
Asset Turnover0.370.3690.4052
Decreasing
Slightly volatile
Payout Ratio2.842.6270.9938
Increasing
Slightly volatile
Enterprise Value over EBITDA17.9216.53716.4818
Increasing
Slightly volatile
Enterprise Value over EBIT18.1117.016.3732
Increasing
Slightly volatile
Price to Earnings Ratio20.3118.49418.8642
Increasing
Stable
Sales per Share20.0921.06221.1347
Decreasing
Slightly volatile
Price to Sales Ratio4.444.4963.7442
Increasing
Slightly volatile
Price to Book Value3.573.9452.7143
Increasing
Slightly volatile
Debt to Equity Ratio1.061.1320.8171
Increasing
Slightly volatile
Dividend Yield0.150.1420.0534
Increasing
Slightly volatile
Current Ratio1.051.0441.1883
Decreasing
Slightly volatile
Free Cash Flow per Share5.85.6694.8968
Increasing
Slightly volatile
Book Value per Share29.6524.00329.5605
Increasing
Stable
Tangible Assets Book Value per Share30.6927.28428.6645
Increasing
Stable

Novartis Valuation Data

Current ValueLast YearHistorical Average 10 Year Trend
Earnings per Basic Share5.25.124.41
Increasing
Slightly volatile
Earnings per Diluted Share5.155.064.367
Increasing
Slightly volatile
Earnings before Tax13.9 B13.5 B11.9 B
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization EBITDA14.8 B14.4 B12.7 B
Increasing
Slightly volatile
Earnings per Basic Share USD5.25.124.41
Increasing
Slightly volatile
Earnings Before Interest Taxes and Depreciation Amortization USD14.8 B14.4 B12.7 B
Increasing
Slightly volatile
Dividends per Basic Common Share14.5113.4524.4935
Increasing
Slightly volatile
Market Capitalization218.1 B218.8 B185.5 B
Increasing
Slightly volatile
Enterprise Value236.3 B237.7 B200.3 B
Increasing
Slightly volatile
Invested Capital60.9 B53 B57.8 B
Increasing
Stable
Average Equity75.2 B67 B70.3 B
Increasing
Slightly volatile
Average Assets140.6 B132 B125.6 B
Increasing
Slightly volatile
Invested Capital Average62.8 B56.9 B57.1 B
Increasing
Slightly volatile
Tangible Asset Value71.6 B63.1 B67.5 B
Increasing
Stable
Return on Average Equity0.180.1750.1504
Increasing
Stable
Return on Average Assets0.08210.0890.0829
Decreasing
Very volatile
Free Cash Flow13.5 B13.1 B11.5 B
Increasing
Slightly volatile
Return on Invested Capital0.260.2530.2255
Increasing
Stable
Gross Margin0.660.7040.6822
Decreasing
Slightly volatile
Profit Margin0.240.2410.2093
Increasing
Slightly volatile
EBITDA Margin0.30.2950.2549
Increasing
Slightly volatile
Return on Sales0.30.2950.2549
Increasing
Slightly volatile
Asset Turnover0.370.3690.4052
Decreasing
Slightly volatile
Payout Ratio2.842.6270.9938
Increasing
Slightly volatile
Enterprise Value over EBITDA17.9216.53716.4818
Increasing
Slightly volatile
Enterprise Value over EBIT18.1117.016.3732
Increasing
Slightly volatile
Price to Earnings Ratio20.3118.49418.8642
Increasing
Stable
Sales per Share20.0921.06221.1347
Decreasing
Slightly volatile
Price to Sales Ratio4.444.4963.7442
Increasing
Slightly volatile
Price to Book Value3.573.9452.7143
Increasing
Slightly volatile
Debt to Equity Ratio1.061.1320.8171
Increasing
Slightly volatile
Dividend Yield0.150.1420.0534
Increasing
Slightly volatile
Current Ratio1.051.0441.1883
Decreasing
Slightly volatile
Working Capital1.3 B1.2 B4.5 B
Decreasing
Slightly volatile
Free Cash Flow per Share5.85.6694.8968
Increasing
Slightly volatile
Book Value per Share29.6524.00329.5605
Increasing
Stable
Tangible Assets Book Value per Share30.6927.28428.6645
Increasing
Stable

Novartis Fundamental Market Drivers

Forward Price Earnings14.11
Shares Short Prior Month2.4M
Average Daily Volume Last 10 Day1.13M
Average Daily Volume In Three Month1.91M
Date Short Interest15th of June 2020
Fifty Day Average87.15
Two Hundred Day Average88.08

Novartis Upcoming Events

Upcoming Quarterly Report21st of July 2020
Next Earnings Report27th of October 2020
Next Fiscal Quarter End30th of June 2020
Next Fiscal Year End3rd of February 2021
Last Quarter Report31st of March 2020
Last Earning Announcement30th of June 2019

About Novartis Financial Statement Charts

There are typically three primary documents that fall into the category of financial statements. These documents include Novartis income statement, its balance sheet, and the statement of cash flows. Novartis investors use historical funamental indicators, such as Novartis's revenue or net income, to determine how well the company is positioned to perform in the future. Although Novartis investors may use each financial statement separately, they are all related. The changes in Novartis's assets and liabilities, for example, are also reflected in the revenues and expenses that we see on Novartis's income statement, which results in the company's gains or losses. Cash flows can provide more information regarding cash listed on a balance sheet, but not equivalent to net income shown on the income statement. We offer a historical overview of the basic patterns found on Novartis Financial Statements. Understanding these patterns can help to make the right decision on long term investment in Novartis. Please read more on our technical analysis and fundamental analysis pages.
 2017 2018 2019 2020 (projected)
Current Assets28.21 B35.56 B29.5 B32.46 B
Total Assets133.08 B145.56 B118.37 B134.45 B

Current Sentiment - NVS

Novartis AG Investor Sentiment

Predominant part of Macroaxis users are now bullish on Novartis AG. What is your trading attitude regarding investing in Novartis AG? Are you bullish or bearish?
Bullish
Bearish
98% Bullish
2% Bearish
Skip

Build Optimal Portfolios

Align your risk with return expectations

Fix your portfolio
By capturing your risk tolerance and investment horizon Macroaxis technology of instant portfolio optimization will compute exactly how much risk is acceptable for your desired return expectations
Additionally, see the analysis of Novartis Correlation with competitors. Please also try Alpha Finder module to use alpha and beta coefficients to find investment opportunities after accounting for the risk.
Macroaxis is not a registered investment advisor or broker/dealer. All investments, including stocks, funds, ETFs, or cryptocurrencies, are speculative and involve substantial risk of loss. We encourage our investors to invest carefully. Much of our information is derived directly from data published by companies or submitted to governmental agencies which we believe are reliable, but are without our independent verification. Therefore, we cannot assure you that the information is accurate or complete. We do not in any way warrant or guarantee the success of any action you take in reliance on our statements or recommendations. Also, note that past performance is not necessarily indicative of future results. All investments carry risk, and all investment decisions of an individual remain the responsibility of that individual. There is no guarantee that systems, indicators, or signals will result in profits or that they will not result in losses. All investors are advised to fully understand all risks associated with any investing they choose to do. Hypothetical or simulated performance is not indicative of future results. We make no representations or warranties that any investor will, or is likely to, achieve profits similar to those shown because hypothetical or simulated performance is not necessarily indicative of future results. For more information please visit our terms and condition page